Transfusion-related risks of intradermal allogeneic lymphocyte immunotherapy: Single cases in a large cohort and review of the literature

American Journal of Reproductive Immunology

Volumn 56, Issue 3, 2006, Pages 157-171

  Kling, Christiane ^a   Steinmann, Jörg ^a   Flesch, Brigitte ^a   Westphal, Eckhard ^a   Kabelitz, Dieter ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Abortion; Human immunodeficiency virus; In vitro fertilization; Leukocyte; Neonatal alloimmune thrombocytopenia; Rhesus hemolytic disease

Indexed keywords

HLA ANTIBODY; IMMUNOGLOBULIN A; THROMBOCYTE ANTIGEN;

ALLOIMMUNIZATION; ANAPHYLAXIS; BLOOD SAMPLING; CANCER; COHORT ANALYSIS; FEMALE; FERTILIZATION IN VITRO; FOLLOW UP; GENOTYPE; GRAFT REJECTION; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INFECTION; INFERTILITY THERAPY; LYMPHOCYTE TRANSFUSION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEWBORN HEMOLYTIC DISEASE; NIDATION; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PURPURA; QUESTIONNAIRE; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SPONTANEOUS ABORTION; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT INDICATION;

ABORTION, HABITUAL; FEMALE; FERTILIZATION IN VITRO; HUMANS; IMMUNOTHERAPY; INFERTILITY; LYMPHOCYTE TRANSFUSION; MALE; META-ANALYSIS; PREGNANCY;

EID: 33746631829     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/j.1600-0897.2006.00413.x     Document Type: Review

References (73)

1. Recurrent Miscarriage Immunotherapy Trialists Group. Worldwide collaborative observational study and meta-analysis on allogenic leukocyte immunotherapy for recurrent spontaneous abortion. Am J Reprod Immunol 1994; 32: 55-72.
2. Kuhn U, Campo R, Hinney B, Neumeyer H, Criel A, Gordts S, Kuhn W. Improvement of pregnancy rates in sterility patients by immunization with paternal lymphocytes. Z Geburtshilfe Perinatol 1993; 197: 209-214 (in German).
3. Check JH, Liss J, Check ML, Diantonio A, Choe JK, Graziano V. Leukocyte immunotherapy improves live delivery rates following embryo transfer in women with at least two previous failures: A retrospective review. Clin Exp Obstet Gynecol 2005; 32: 85-88.
4. Beer AE, Semprini AE, Zhu XY, Quebbeman JF. Pregnancy outcome in human couples with recurrent spontaneous abortions: HLA antigen profiles; HLA antigen sharing; female serum MLR blocking factors; and paternal leukocyte immunization. Exp Clin Immunogenet 1985; 2: 137-153.
5. Kling C, Magez J, Jenisch S, Kabelitz D. Experience with allogeneic leukocyte immunization for implantation failure in the in-vitro fertilization program. Am J Reprod Immunol 2002; 48: 147.
6. Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev 2003; CD000112.
7. Christiansen OB, Nielsen HS, Pedersen B. Active or passive immunization in unexplained recurrent miscarriage. J Reprod Immunol 2004; 62: 41-52.
8. Clark DA, Coulam CB, Daya S, Chaouat G. Unexplained sporadic and recurrent miscarrage in the new millennium: A critical analysis of immune mechanisms and treatments. Hum Reprod Update 2001; 7: 501-511.
9. Takeshita T. Diagnosis and treatment of recurrent miscarriage associated with immunologic disorders: Is paternal lymphocyte immunization a relic of the past? J Nippon Med Sch 2004; 71: 308-313.
10. Lam GK, Subramanyam L, Orton S, Farb R, Moise KJ, Jr. Minimizing red blood cell contamination while isolating mononuclear cells from whole blood: The next step for the treatment of severe hemolytic disease of the fetus/newborn. Am J Obstet Gynecol 2003; 189: 1012-1016.
11. Neppert J, Witzleben-Schurholz E, Zupanska B, Bartz L, Greve O, Eichler H, Kerowgan M, Wichmann MG. High incidence of maternal HLA A, B and C antibodies associated with a mild course of haemolytic disease of the newborn. Group for the Study of Protective Maternal HLA Antibodies in the Clinical Course of HDN. Eur J Haematol 1999; 63: 120-125.
12. Quayle AJ, Fidel P, Jr, Rosenberg ES. Sex, alloimmunisation, and susceptibility to HIV infection. Lancet 2004; 363: 503-504.
13. Kling C, Steinmann J, Westphal E, Magez J, Kabelitz D. Adverse effects of intradermal allogeneic lymphocyte immunotherapy: Acute reactions and role of autoimmunity. Hum Reprod 2006; 21: 429-435.
14. Hopkins K. The basic lymphocyte microcytotoxicity tests: Standard and AHG enhancement. In ASHI Laboratory Manual, A Hahn, G Land, R Strothman (eds). Mt Laurel, NJ, American Society for Histocompatibility and Immunogenetics, 2000, Sect. I.C.1 pp.1-7, Sect. I.C.13 pp. 1-15.
15. Pidwell D. Interpretation of crossmatch results. In ASHI Laboratory Manual, A Hahn, G Land, R Strothman (eds). Mt Laurel, NJ, American Society for Histocompatibility and Immunogenetics, 2000, pp I.C.13-1-15.
16. Klüter H, Fehlau K, Panzer S, Kirchner H, Bein G. Rapid typing for human platelet antigen systems-1, -2, -3 and -5 by PCR amplification with sequence-specific primers. Vox Sang 1996; 71: 121-125.
17. Agrawal S, Kishore R, Halder A, Sharma A, Sharma RK, Das V, Shukla BR, Agarwal SS. Outcome of pregnancy in women with recurrent spontaneous abortion following immunotherapy with allogeneic lymphocytes. Hum Reprod 1995; 10: 2280-2284.
18. Aoki K, Matsumoto Y, Tsuji A, Ozaki Y, Kajiura S, Kimbara T, Yagami Y. The evidence of safety of immunotherapy for unexplained habitual aborters. Nippon Sanka Fujinka Gakkai Zasshi 1992; 44: 405-411 (in Japanese).
19. Carp HJ, Toder V, Gazit E, Orgad S, Mashiach S, Nebel L, Serr DM. Immunization by paternal leukocytes for prevention of primary habitual abortion: Results of a matched controlled trial. Gynecol Obstet Invest 1990; 29: 16-21.
20. Ho HN, Gill TJ, III, Hsieh HJ, Jiang JJ, Lee TY, Hsieh CY. Immunotherapy for recurrent spontaneous abortions in a Chinese population. Am J Reprod Immunol 1991; 25: 10-15.
21. Jerzak M, Rechberger T, Baranowski W, Semczuk M. Immunotherapy as an effective treatment of recurrent spontaneous abortion - Own experience. Ginekol Pol 2003; 74: 1107-1111 (in Polish).
22. Li TC, MacLeod I, Duncan SLB. The obstetric and neonatal outcome of pregnancy in women with a previous history of infertility: A prospective study. Br J Obstet Gynaecol 1991; 98: 1087-1092.
23. Malinowski A, Prochowska A, Banasik M, Wilczynski J, Szpakowski M, Zeman K, Oszukowski P, Lerch E. Clinical and immunological condition of newborns of mothers treated for recurrent spontaneous abortions with paternal lymphocytes immunization. Eur J Obstet Gynecol Reprod Biol 1997; 73: 55-61.
24. Takakuwa K, Goto S, Hasegawa I, Ueda H, Maruhashi T, Kajino T, Yoshizawa H, Kanazawa K, Takeuchi S. Is immunotherapy for habitual aborters an immunologically hazardous procedure for infants? Am J Reprod Immunol 1989; 19: 53-56.
25. Bux J, Westphal E, de Sousa F, Mueller-Eckhardt G, Mueller-Eckhardt C. Alloimmune neonatal neutropenia is a potential side effect of immunization with leukocytes in women with recurrent spontaneous abortions. J Reprod Immunol 1992; 22: 299-302.
26. Pearlman SA, Meek RS, Cowchock FS, Smith JB, McFarland J, Aster RH: Neonatal alloimmune thrombocytopenia after maternal immunization with paternal mononuclear cells: Successful treatment with intravenous gamma globulin. Am J Perinatol 1992; 9: 448-451.
27. Tanaka T, Umesaki N, Maeda K, Miyama M, Ogita S: Pregnancy and neonatal outcomes in unexplained recurrent/habitual aborters treated by allogenic leukocyte immunization. Osaka City Med J 1997; 43: 81-87.
28. Christiansen OB, Mathiesen O, Husth M, Lauritsen JG, Grunnet N: Placebo-controlled trial of active immunization with third party leukocytes in recurrent miscarriage. Acta Obstet Gynecol Scand 1994; 73: 261-268.
29. Dupont E, Moriaux M, Lambermont M, Englert Y: Re-evaluation of immunomodulator treatments for recurrent abortions. Rev Med Brux 1998; 19: 69-72 (in French).
30. Tanaka T, Umesaki N, Nishio J, Maeda K, Kawamura T, Araki N, Ogita S: Neonatal thrombocytopenia induced by maternal anti-HLA antibodies: A potential side effect of allogenic leukocyte immunization for unexplained recurrent aborters. J Reprod Immunol 2000; 46: 51-57.
31. Caspari G, Gerlich WH: Infections transmitted by blood products. In. Transfusion Medicine, C Mueller-Eckhardt, V Kiefel (eds). Berlin, Springer, 2004, pp 599-645 (in German).
32. Council of Europe: Guide to the Preparation, Use and Quality Assurance of Blood Components. F-67075 Strasbourg Cedex, Council of Europe, 2004.
33. Combs MR, Drew MJ, Goodnough LT, Grossman BJ: Technical Manual aaBB. Bethesda, MD, American Association of Blood Banks, 2002.
34. Doerr HW: Cytomegalovirus infection in pregnancy. J Virol Methods 1987; 17: 127-132.
35. McMonigal K, Horwitz CA, Henle W, Henle G, Lawton J, Polesky H, Peterson L: Post-perfusion syndrome due to Epstein-Barr virus. Report of two cases and review of the literature. Transfusion 1983; 23: 331-335.
36. Regan L, Braude PR, Hill DP: A prospective study of the incidence, time of appearance and significance of anti-paternal lymphocytotoxic antibodies in human pregnancy. Hum Reprod 1991; 6: 294-298.
37. Morin-Papunen L, Tiilikainen A, Hartikainen-Sorri AL: Maternal HLA immunization during pregnancy: Presence of anti-HLA antibodies in half of multigravidous women. Med Biol 1984; 62: 323-325.
38. Winter PM, Manndorff P: The frequency of IgA-deficiency in the Austrian population. A protocol for large-scale screening by ELISA and a study on 3056 blood donors. Infusionstherapie 1988; 15: 221-224.
39. Ulfarsson J, Gudmundsson S, Birgisdottir B, Kjeld JM, Jensson O: Selective serum IgA deficiency in Icelanders. Frequency, family studies and Ig levels. Acta Med Scand 1982; 211: 481-487.
40. Koskinen S, Tolo H, Hirvonen M, Koistinen J: Long-term follow-up of anti-IgA antibodies in healthy IgA-deficient adults. J Clin Immunol 1995; 15: 194-198.
41. Kleinman S, Chan P, Robillard P: Risks associated with transfusion of cellular blood components in canada. Transfus Med Rev 2003; 17: 120-162.
42. Porcelijn L, dem Borne AE: ImBune-mediated thrombocytopenias: basic and immunological aspects. Baillieres Clin Haematol 1998; 11: 331-341.
43. Chaouat G, Ledee-Bataille N, Dubanchet S, Zourbas S, Sandra O, Martal J: TH1/TH2 paradigm in pregnancy: Paradigm lost? Cytokines in pregnancy/ early abortion: Reexamining the TH1/TH2 paradigm. Int Arch Allergy Immunol 2004; 134: 93-119.
44. Haberal M, Karakayali H, Emiroglu R, Basaran O, Moray G, Bilgin N: Malignant tumors after renal transplantation. Artif Organs 2002; 26: 778-781.
45. Lapierre V, Auperin A, Tiberghien P: Transfusion-induced immunomodulation following cancer surgery: Fact or fiction ? J Natl Cancer Inst 1998; 90: 573-580.
46. Vamvakas E, Moore SB: Perioperative blood transfusion and colorectal cancer recurrence: A qualitative statistical overview and meta-analysis. Transfusion 1993; 33: 754-765.
47. Busch OR, Hop WC, Hoynck van Papendrecht MA, Marquet RL, Jeekel J: Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993; 328: 1372-1376.
48. Heiss MM, Mempel W, Delanoff C, Jauch KW, Gabka C, Mempel M, Dieterich HJ, Eissner HJ, Schildberg FW: Blood transfusion-modulated tumor recurrence: First results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994; 12: 1859-1867.
49. Vamvakas EC, Blajchman MA: Deleterious clinical effects of transfusion-associated immunomodulation: Fact or fiction? Blood 2001; 97: 1180-1195.
50. Filbey D, Hanson U, Wesstrom G: The prevalence of red cell antibodies in pregnancy correlated to the outcome of the newborn: A 12 year study in central Sweden. Acta Obstet Gynecol Scand 1995; 74: 687-692.
51. Hadley AG: Laboratory assays for predicting the severity of haemolytic disease of the fetus and newborn. Transpl Immunol 2002; 10: 191-198.
52. Eichler H, Zieger W, Neppert J, Kerowgan M, Melchert F, Goldmann SF: Mild course of fetal RhD haemolytic disease due to maternal alloimmunisation to paternal HLA class I and II antigens. Vox Sang 1995; 68: 243-247.
53. Dooren MC, van Kamp IL, Kanhai HH, Gravenhorst JB, dem Borne AE, Engelfriet CP: Evidence for the protective effect of maternal FcR-blocking IgG alloantibodies HLA-DR in Rh D-haemolytic disease of the newborn. Vox Sang 1993; 65: 55-58.
54. Kaplan C: Alloimmune thrombocytopenia of the fetus and the newborn. Blood Rev 2002; 16: 69-72.
55. Davoren A, Curtis BR, Aster RH, McFarland JG: Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Transfusion 2004; 44: 1220-1225.
56. King KE, Kao KJ, Bray PF, Casella JF, Blakemore K, Callan NA, Kennedy SD, Kickler TS: The role of HLA antibodies in neonatal thrombocytopenia: a prospective study. Tissue Antigens 1996; 47: 206-211.
57. Panzer S, Eichelberger B: Controversy: HLA-antibodies responsible for NAITP? Transfus Med Hemother 2005; 32 (S1): 5.
58. Davoren A, McParland P, Crowley J, Barnes A, Kelly G, Murphy WG: Antenatal screening for human platelet antigen-1a: Results of a prospective study at a large maternity hospital in Ireland. BJOG 2003; 110: 492-496.
59. Williamson LM, Hackett G, Rennie J, Palmer CR, Maciver C, Hadfield R, Hughes D, Jobson S, Ouwehand WH: The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood 1998; 92: 2280-2287.
60. Uhrynowska M, Maslanka K, Zupanska B: Neonatal thrombocytopenia: incidence, serological and clinical observations. Am J Perinatol 1997; 14: 415-418.
61. Uhrynowska M, Niznikowska-Marks M, Zupanska B: Neonatal and maternal thrombocytopenia: Incidence and immune background. Eur J Haematol 2000; 64: 42-46.
62. Dreyfus M, Kaplan C, Verdy E, Schlegel N, Durand-Zaleski I, Tchernia G: Frequency of immune thrombocytopenia in newborns: A prospective study. Immune Thrombocytopenia Working Group. Blood 1997; 89: 4402-4406.
63. Beiner ME, Simchen MJ, Sivan E, Chetrit A, Kuint J, Schiff E: Risk factors for neonatal thrombocytopenia in preterm infants. Am J Perinatol 2003; 20: 49-54.
64. Gopel W, Fehlau K, Kohl M, Schultz C, Moller J: HPA-1 carrier status and thrombocytopenia in preterm infants with a birth weight below 1500 grams. J Perinat Med 2002; 30: 176-178.
65. Vergani P, Locatelli A, Doria V, Assi F, Paterlini G, Pezzullo JC, Ghidini A: Intraventricular hemorrhage and periventricular leukomalacia in preterm infants. Obstet Gynecol 2004; 104: 225-231.
66. Hansen M, Kurinczuk JJ, Bower C, Webb S: The risk of major birth defects after intracytoplasmic sperm injection and in vitro fertilization. N Engl J Med 2002; 346: 725-730.
67. Bonduelle M, Liebaers I, Deketelaere V, Derde MP, Camus M, Devroey P, Van Steirteghem A: Neonatal data on a cohort of 2889 infants born after ICSI (1991-1999) and of 2995 infants born after IVF (1983-1999). Hum Reprod 2002; 17: 671-694.
68. Hinkel GK, Schneider I, Gebhardt B, Leverenz S: Alloimmune neonatal neutropenia: Clinical observations and therapeutic results. Schweiz Med Wochenschr 1985; 115: 831-836 (in German).
69. Bux J: Molecular nature of antigens implicated in immune neutropenias. Int J Hematol 2002; 76 (Suppl. 1): 399-403.
70. Maheshwari A, Christensen RD, Calhoun DA: Immune-mediated neutropenia in the neonate. Acta Paediatr Suppl 2002; 91: 98-103.
71. Zupanska B, Uhrynowska M, Guz K, Maslanka K, Brojer E, Czestynska M, Radomska I: The risk of antibody formation against HNA1a and HNA1b granulocyte antigens during pregnancy and its relation to neonatal neutropenia. Transfus Med 2001; 11: 377-382.
72. Bux J, Jung KD, Kauth T, Mueller-Eckhardt C: Serological and clinical aspects of granulocyte antibodies leading to alloimmune neonatal neutropenia. Transfus Med 1992; 2: 143-149.
73. Ballabh P, Kumari J, AlKouatly HB, Yih M, Arevalo R, Rosenwaks Z, Krauss AN: Neonatal outcome of triplet versus twin and singleton preAnancies: a matched case control study. Eur J Obstet Gynecol Reprod Biol 2003; 107: 28-36.